Positive Clinical Trial Results of Echo Therapeutics Symphony CGM System to be Presented at the 74th Scientific Sessions of the American Diabetes Association
PHILADELPHIA, June 5, 2014 /PRNewswire/ — Echo Therapeutics, Inc. (Nasdaq: ECTE) (“Echo”), a medical device company developing its Symphony(®) CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.
The study will be presented by the principal investigator, Jeffrey I. Joseph, D.O., Vice-Chairman and Director of Research, Department of Anesthesiology and Director of the Artificial Pancreas Center at Thomas Jefferson University in Philadelphia, PA, during poster presentations on Sunday, June 15, 2014 at 12:00 – 2:00 p.m. PT. The poster, entitled “Performance of the Symphony CGM System in Critically Ill Diabetic and Non-Diabetic Patients” (868-P), will provide an expanded analysis of data collected from the multi-center clinical trial of Echo’s Symphony CGM System in post-surgical diabetic and non-diabetic patients in hospital intensive care units (ICUs).
“The Symphony CGM System demonstrated clinically relevant accuracy and excellent safety in ICU patients. While approximately 30% of critically ill patients have a history of diabetes, poor glucose control can occur in patients with or without diabetes resulting in increased length of stay and costs,” commented Dr. Joseph. “A continuous glucose monitoring system that is safe, accurate and user-friendly will become an important clinical tool for maintaining glucose control in diabetic and non-diabetic hospitalized patients.”
Previous clinical study results of the Symphony CGM System have also been presented at various medical conferences and published in medical journals. This May, data from an earlier study of Symphony were published in the Journal of Diabetes Science and Technology.
About Echo Therapeutics
Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device, the Prelude(®) SkinPrep System, as a platform technology to enhance delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts, including the statement about Dr. Joseph’s poster presentation, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s ongoing studies, including the safety and efficacy of Echo’s Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo’s Symphony CGM System, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
SOURCE Echo Therapeutics, Inc.